Physicians warn that non-alcoholic fatty liver disease is increasingly affecting children, often going undetected until serious liver damage has already begun.
By yourNEWS Media Newsroom
Once largely associated with adults and alcohol-related illness, fatty liver disease is now emerging as a major pediatric health concern, driven largely by rising rates of childhood obesity and metabolic dysfunction. Non-alcoholic fatty liver disease, or NAFLD, is estimated to affect about 36% of obese children and roughly 10% of the overall pediatric population, a prevalence that has more than doubled since 2017.
NAFLD is characterized by excessive fat accumulation in liver cells unrelated to alcohol use. Over time, the condition can progress to inflammation, scarring, cirrhosis, liver failure and liver cancer. Medical researchers project that NAFLD will become the leading cause of liver transplants by 2030, underscoring the long-term consequences of early-onset disease.
In recent years, experts have increasingly adopted the term metabolic dysfunction–associated fatty liver disease, or MAFLD, to better reflect the condition’s close association with obesity, insulin resistance and broader metabolic disorders. While most pediatric cases meet criteria for both NAFLD and MAFLD, researchers note that approximately 19% of affected children have normal weight and normal blood sugar levels, complicating diagnosis and screening.
Emerging evidence suggests that factors beyond weight alone may contribute to disease development. Studies examining gut microbiome composition have identified differences between children with fatty liver disease and those without, pointing to a possible role for microbial imbalance in liver inflammation and fat accumulation. Researchers have proposed that disruptions in the gut barrier may allow toxins and bacteria to enter the bloodstream, triggering metabolic dysfunction and liver injury.
Despite its growing prevalence, pediatric fatty liver disease is frequently underdiagnosed. Many children show no outward symptoms until significant liver damage has occurred. Standard blood tests that measure liver enzymes often fail to detect the disease, with a substantial portion of affected children showing normal results. Ultrasound imaging can miss early-stage disease, while more accurate tools such as MRI scans are expensive and not routinely used. Liver biopsy remains the definitive diagnostic method but is invasive and reserved for selected high-risk cases.
The condition typically develops when excess fat accumulates in liver cells due to poor diet, low physical activity and impaired metabolic regulation. As inflammation progresses, some children develop non-alcoholic steatohepatitis, or NASH, which can lead to permanent scarring and eventual liver failure. Even when liver disease does not advance to severe stages during childhood, affected children face higher risks of developing Type 2 diabetes, cardiovascular disease and metabolic syndrome later in life.
Obesity remains the strongest risk factor. National survey data indicate that nearly one in five U.S. children is obese, with an additional portion classified as overweight. Research also shows that children with normal body mass index but excess abdominal fat are vulnerable, highlighting the limitations of weight-based screening alone.
Currently, there are no FDA-approved medications to treat pediatric NAFLD. Medical guidance focuses on lifestyle interventions, including weight reduction, increased physical activity and dietary changes. Reducing sugar intake—particularly fructose from sugary drinks and processed foods—has been identified as a key strategy for lowering liver fat and improving metabolic health.
While progression to end-stage liver disease is uncommon during childhood, clinicians emphasize that NAFLD diagnosed early in life can set the stage for severe liver damage in adulthood. Disease progression in adults often occurs over several years per stage, raising concern that children affected today could face cirrhosis or liver failure in early adulthood if no intervention occurs.
Health experts continue to call for improved screening strategies, broader public education on metabolic health and early lifestyle interventions aimed at at-risk children. Without changes in detection and prevention, pediatric fatty liver disease is expected to place increasing strain on healthcare systems in the coming decades.
Learn how to treat fatty liver disease in kids by watching this video.
This video is from the Daily Videos channel on Brighteon.com.
Source: Natural News
Original article
Comments